Chargelegue D, Obeid O E, Shaw D M, Denbury A N, Hobby P, Hsu S C, Steward M W
London School of Hygiene and Tropical Medicine, Molecular Immunology Unit, UK.
Immunol Lett. 1997 Jun 1;57(1-3):15-7. doi: 10.1016/s0165-2478(97)00045-x.
To identify peptides that mimic (mimotopesi conformational and protective epitopes of RSV fusion protein and to assess their efficacy as immunogens and potential vaccines.
An 8-mer solid-phase (TG resin) library was screened with a neutralising and protective RSV fusion protein specific monoclonal antibodies (Mab-19). After selection of positive beads, reactive sequences were identified by microsequencing and 8-mer peptides were synthesised. Improvement of binding was analysed by amino acid replacement using the SPOTs method.
Mabs were not able to bind to the free and soluble peptides, nor did these peptides induce anti-RSV specific antibodies. However, several peptides re-synthesised on a TG resin (to produce de-protected 8-mer peptides linked to the resin) or as SPOTs reacted specifically. Therefore it was critical to be able to reproduce this conformation in order to use these mimotopes as immunogens and potential vaccines. Using C-terminal constrained versions of the mimotopes, strong binding of one of the Mabs to the peptides was demonstrated by surface-plasmon resonance. Immunisation of Balb/c mice with these peptide-mimics produced anti-sera that: (1) reacted specifically with RSV; (2) inhibited the binding of the Mab to the virus; (3) neutralised RSV in vitro with high titres (range: 80-640); and (4) reduce significantly the viral load in the lungs of mice challenged with RSV (P < 0.01).
This report demonstrates for the first time that: (1) a protective epitope of the conserved RSV fusion protein can be mimicked by synthetic peptides; and (2) immunisations with these mimotopes induced specific anti-RSV neutralising antibodies and reduced viral load in vivo. These results represent a novel concept for the development of a vaccine against RSV.
鉴定模拟呼吸道合胞病毒(RSV)融合蛋白构象和保护性表位的肽段,并评估其作为免疫原和潜在疫苗的效力。
用一种具有中和及保护作用的、针对RSV融合蛋白的特异性单克隆抗体(Mab-19)筛选一个8肽固相(TG树脂)文库。选择阳性珠子后,通过微量测序鉴定反应性序列并合成8肽。使用SPOTs方法通过氨基酸替换分析结合的改善情况。
单克隆抗体不能与游离和可溶性肽结合,这些肽也不能诱导抗RSV特异性抗体。然而,在TG树脂上重新合成的几种肽(以产生与树脂相连的去保护8肽)或作为SPOTs时发生了特异性反应。因此,为了将这些模拟表位用作免疫原和潜在疫苗,能够重现这种构象至关重要。使用模拟表位的C端受限版本,通过表面等离子体共振证明其中一种单克隆抗体与肽有强结合。用这些肽模拟物免疫Balb/c小鼠产生的抗血清:(1)与RSV特异性反应;(2)抑制单克隆抗体与病毒的结合;(3)在体外以高滴度(范围:80 - 640)中和RSV;(4)显著降低用RSV攻击的小鼠肺部的病毒载量(P < 0.01)。
本报告首次证明:(1)合成肽可模拟RSV保守融合蛋白的保护性表位;(2)用这些模拟表位免疫可诱导特异性抗RSV中和抗体并降低体内病毒载量。这些结果代表了开发抗RSV疫苗的一个新概念。